AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9857661 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment (20 mg/d for 14 days)
Number of subjects: 20
Study 9857661 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (N=22)
Number of subjects: 20
Study 7609198 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stage epispadias reconstruction with dissection of the corporo (30 patients)
Number of subjects: 180
Study 7609198 — intervention group
Group type: EXPERIMENTAL
Intervention: pedicled preputial tube urethroplasty either alone or with a lyophilized human dural patch (35 patients)
Number of subjects: 180
Study 7609198 — intervention group
Group type: EXPERIMENTAL
Intervention: pedicled preputial tube urethroplasty and corporeal rotation (40 patients)
Number of subjects: 180
Study 7609198 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Cantwell epispadias repair incorporating complete tubularized urethroplasty, cavernocavernostomy and corporeal rotation
Number of subjects: 180
Study 2172175 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/kg body weight FDP
Number of subjects: 10
Study 2172175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 419426 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine solution irrigation
Number of subjects: 500
Study 419426 — intervention group
Group type: COMPARATOR
Intervention: Saline solution irrigation
Number of subjects: 500
Study 30760183 — intervention group
Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (late-PN)
Number of subjects: 982
Study 30760183 — intervention group
Group type: COMPARATOR
Intervention: Early parenteral nutrition (early-PN)
Number of subjects: 982
Study 27574821 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI/transrectal ultrasound fusion software‐guided targeted biopsy (TB)
Number of subjects: 212
Study 27574821 — intervention group
Group type: COMPARATOR
Intervention: Standard biopsy (SB)
Number of subjects: 212
Study 27574821 — intervention group
Group type: EXPERIMENTAL
Intervention: TB in arm A
Number of subjects: 212
Study 27574821 — intervention group
Group type: EXPERIMENTAL
Intervention: SB in arm A
Number of subjects: 212
Study 27574821 — intervention group
Group type: EXPERIMENTAL
Intervention: SB in arm B
Number of subjects: 212
Study 25789261 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 20 mg
Number of subjects: 104
Study 25789261 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 30 mg
Number of subjects: 104
Study 25789261 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 104
Study 25789261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 23982635 — intervention group
Group type: EXPERIMENTAL
Intervention: Harvesting the semitendinosus tendon only
Number of subjects: 150
Study 23982635 — intervention group
Group type: EXPERIMENTAL
Intervention: Harvesting the semitendinosus and gracilis tendons
Number of subjects: 150
Study 23982635 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerated semitendinosus tendon
Number of subjects: 150
Study 23982635 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic strength assessment
Number of subjects: 150
Study 23982635 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroscopic and histological analysis of regenerated tendons
Number of subjects: 150
Study 23982635 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of regenerated tendon
Number of subjects: 150
Study 21353334 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol
Number of subjects: 38
Study 21353334 — intervention group
Group type: COMPARATOR
Intervention: Pimecrolimus
Number of subjects: 38
Study 19636533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (target BG 4.4-6.1 mmol/L)
Number of subjects: 1078
Study 19636533 — intervention group
Group type: COMPARATOR
Intervention: Intermediate glucose control (target BG 7.8-10.0 mmol/L)
Number of subjects: 1078
Study 17470885 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg iv
Number of subjects: 90
Study 17470885 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg iv
Number of subjects: 90
Study 15743156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (five educational sessions)
Number of subjects: 140
Study 15743156 — intervention group
Group type: COMPARATOR
Intervention: Medical recommendations (standard written diet instructions)
Number of subjects: 140
Study 15743156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 140
Study 15743156 — intervention group
Group type: COMPARATOR
Intervention: Medical recommendations
Number of subjects: 140
Study 15743156 — intervention group
Group type: COMPARATOR
Intervention: Nutritional intervention and Medical recommendations
Number of subjects: 140
Study 11552910 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 40
Study 11552910 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic dilatation
Number of subjects: 40
Study 9558744 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyen
Number of subjects: 0
Study 9558744 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 7631085 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor cortex stimulation (3 patients); pulse duration 0.1‐0.5 ms; intensity 3‐8 V
Number of subjects: 6
Study 7631085 — intervention group
Group type: COMPARATOR
Intervention: Thalamic stimulation (4 patients)
Number of subjects: 6
Study 2889459 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 0
Study 2889459 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol (200 mg)
Number of subjects: 0
Study 30105967 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 146
Study 30105967 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate (PA)
Number of subjects: 146
Study 30105967 — intervention group
Group type: EXPERIMENTAL
Intervention: db-PCR-NALFIA
Number of subjects: 146
Study 30105967 — intervention group
Group type: EXPERIMENTAL
Intervention: qPCR
Number of subjects: 146
Study 28267591 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (Trier Social Stress Test)
Number of subjects: 63
Study 28267591 — intervention group
Group type: COMPARATOR
Intervention: Control condition (friendly TSST)
Number of subjects: 63
Study 28267591 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 63
Study 26387392 — intervention group
Group type: EXPERIMENTAL
Intervention: Malvastrum coromandelianum (MC) tablets, 1,200 mg/day for 12 weeks
Number of subjects: 71
Study 26387392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 22297124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 459
Study 22297124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 21160309 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program with early mobilization and diet (n = 46)
Number of subjects: 100
Study 21160309 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (n = 54)
Number of subjects: 100
Study 21160309 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program with early mobilization and diet
Number of subjects: 100
Study 21160309 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 100
Study 18996881 — intervention group
Group type: EXPERIMENTAL
Intervention: B-GOS (5.5 g/d)
Number of subjects: 44
Study 18996881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 17167301 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 435
Study 17167301 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight training (WT)
Number of subjects: 435
Study 17167301 — intervention group
Group type: COMPARATOR
Intervention: Health educational (HE)
Number of subjects: 435
Study 14599072 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 32
Study 14599072 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 32
Study 12654764 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-773 (cethromycin) at a dose of 150 mg once a day for 10 days
Number of subjects: 10
Study 12654764 — intervention group
Group type: COMPARATOR
Intervention: ABT-773 (cethromycin) at a dose of 150 mg twice a day for 10 days
Number of subjects: 10
Study 9623220 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 0
Study 9623220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8122724 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation by emergency medical technicians (EMTs) trained in Defibrillation (study group = S)
Number of subjects: 121
Study 8122724 — intervention group
Group type: COMPARATOR
Intervention: Basic life support (BLS) by EMTs and defibrillation by emergency physicians (control group 1 = C1)
Number of subjects: 121
Study 8122724 — intervention group
Group type: COMPARATOR
Intervention: BLS and advanced cardiac life support (ACLS) by emergency physician crews (control group 2 = C2)
Number of subjects: 121
Study 8122724 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation by EMTs (study group = S)
Number of subjects: 121
Study 8122724 — intervention group
Group type: COMPARATOR
Intervention: Defibrillation by emergency physicians (control group 1 = C1)
Number of subjects: 121
Study 8122724 — intervention group
Group type: COMPARATOR
Intervention: Defibrillation by emergency physicians (control group 2 = C2)
Number of subjects: 121
Study 2511743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem 120 mg twice daily
Number of subjects: 65
Study 2511743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem 180 mg twice daily
Number of subjects: 65
Study 2511743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 125389 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine coadministration with levodopa
Number of subjects: 6
Study 125389 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine coadministration with piribedil
Number of subjects: 6
Study 31485817 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary behavior
Number of subjects: 1038
Study 31485817 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 1038
Study 28220376 — intervention group
Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 0
Study 28220376 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 28220376 — intervention group
Group type: COMPARATOR
Intervention: Divalproex
Number of subjects: 0
Study 28220376 — intervention group
Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 0
Study 26281341 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration anesthesia (LIA)
Number of subjects: 54
Study 26281341 — intervention group
Group type: COMPARATOR
Intervention: Peripheral nerve block (PNB)
Number of subjects: 54
Study 22388589 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based peer support (mother-to-mother)
Number of subjects: 349
Study 22090477 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2811376, an orally available non-peptidic BACE1 inhibitor, dosages of 30 mg and 90 mg.
Number of subjects: 0
Study 19723732 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Goals Program (LGP)
Number of subjects: 164
Study 19723732 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 164
Study 17250885 — intervention group
Group type: EXPERIMENTAL
Intervention: Words
Number of subjects: 2
Study 17250885 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestures
Number of subjects: 2
Study 17250885 — intervention group
Group type: EXPERIMENTAL
Intervention: Words and Gestures
Number of subjects: 2
Study 15180223 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management program
Number of subjects: 188
Study 11677506 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention during waiting time
Number of subjects: 100
Study 11677506 — intervention group
Group type: COMPARATOR
Intervention: Usual clinic care (no structured education)
Number of subjects: 100
Study 10218061 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol/xylitol-sweetened chewing gum
Number of subjects: 80
Study 10218061 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol-sweetened sour lemon lozenge
Number of subjects: 80
Study 10218061 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol/xylitol-sweetened artificial saliva substitute spray
Number of subjects: 80
Study 10218061 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline paraffin-stimulated mean flow rate)
Number of subjects: 80
Study 8160944 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin suppositories 200 mg p.r. at the end of anaesthesia, followed by 100 mg bd for three days
Number of subjects: 50
Study 8160944 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories according to the same regimen
Number of subjects: 50
Study 8160944 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin group
Number of subjects: 50
Study 8160944 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 3410354 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide local excision with ipsilateral superficial inguinal lymph node dissection
Number of subjects: 22
Study 3410354 — intervention group
Group type: COMPARATOR
Intervention: Radical vulvectomy with bilateral superficial and deep inguinal lymph node dissection
Number of subjects: 22
Study 31130268 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation Radiofrequency (CR)
Number of subjects: 57
Study 31130268 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation Submucosal Reduction Turbinator (SCT)
Number of subjects: 57
Study 31130268 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 57
Study 27794124 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab
Number of subjects: 1392
Study 27794124 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1392
Study 26343814 — intervention group
Group type: COMPARATOR
Intervention: Empagliflozin (12 weeks, cohort 1)
Number of subjects: 3300
Study 26343814 — intervention group
Group type: COMPARATOR
Intervention: Empagliflozin (24 weeks, cohort 2)
Number of subjects: 3300
Study 26343814 — intervention group
Group type: COMPARATOR
Intervention: Empagliflozin (cohort 1)
Number of subjects: 3300
Study 26343814 — intervention group
Group type: COMPARATOR
Intervention: Empagliflozin (cohort 2)
Number of subjects: 3300
Study 23621201 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Counseling Group (ICG)
Number of subjects: 150
Study 23621201 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Counseling Group (GCG)
Number of subjects: 150
Study 23621201 — intervention group
Group type: COMPARATOR
Intervention: Control Counseling Group (CCG)
Number of subjects: 150
Study 21933348 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin (50 mg or 100 mg/day)
Number of subjects: 738
Study 21933348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 738
Study 19255824 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with 50 mg of losartan plus 12.5 mg of hydrochlorothiazide
Number of subjects: 32
Study 19255824 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with 160 mg of valsartan
Number of subjects: 32
Study 16421661 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral intake supplementation with a formula enriched with arginine, omega-3 fatty acids and ribonucleic acid for five days (supplemented group; n = 19)
Number of subjects: 36
Study 16421661 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 36
Study 15614033 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combination of perindopril (2 mg) and indapamide (0.625 mg)
Number of subjects: 533
Study 15614033 — intervention group
Group type: COMPARATOR
Intervention: Sequential monotherapy (atenolol 50 mg, losartan 50 mg, amlodipine 5 mg)
Number of subjects: 533
Study 15614033 — intervention group
Group type: COMPARATOR
Intervention: Stepped-care (valsartan 40 mg, valsartan 80 mg, hydrochlorothiazide 12.5 mg)
Number of subjects: 533
Study 11159107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulcal hyperintensity on FLAIR images
Number of subjects: 291
Study 11159107 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirty CSF sign
Number of subjects: 291
Study 11159107 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal contrast enhancement
Number of subjects: 291
Study 9404442 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy (0.125 iu/kg/week for the first month and 0.25 iu/kg/week for the following 5 months)
Number of subjects: 30
Study 9404442 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 30
Study 9404442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8115311 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine plain formulation (2.5 mg twice daily)
Number of subjects: 30
Study 8115311 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine slow release formulation (5.0 mg once daily)
Number of subjects: 30
Study 8115311 — intervention group
Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 30
Study 3303424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg daily)
Number of subjects: 10
Study 3303424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3303424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (in asthmatic patients)
Number of subjects: 10
Study 3303424 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in asthmatic patients)
Number of subjects: 10
Study 30874799 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with non-immersive virtual reality intervention
Number of subjects: 39
Study 30874799 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training
Number of subjects: 39
Study 29676870 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide-like diuretics (e.g., chlorthalidone, indapamide)
Number of subjects: 0
Study 29676870 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose thiazide-like diuretics
Number of subjects: 0
Study 29037203 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Nutriathlon (web-based nutrition intervention)
Number of subjects: 282
Study 29037203 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular school curriculum)
Number of subjects: 282
Study 26530748 — intervention group
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy (EBRT)
Number of subjects: 427
Study 26530748 — intervention group
Group type: COMPARATOR
Intervention: Vaginal Brachytherapy (VBT)
Number of subjects: 427
Study 23132892 — intervention group
Group type: EXPERIMENTAL
Intervention: Web/Mail
Number of subjects: 0
Study 23132892 — intervention group
Group type: COMPARATOR
Intervention: Mail Only
Number of subjects: 0
Study 23132892 — intervention group
Group type: EXPERIMENTAL
Intervention: SE-IVR/Phone
Number of subjects: 0
Study 21813076 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (2-15 mg/d)
Number of subjects: 330
Study 17665078 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% propofol
Number of subjects: 60
Study 17665078 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% propofol + 0.5 mg.ml‐1 ephedrine
Number of subjects: 60
Study 17665078 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% propofol + 1.0 mg.ml‐1 ephedrine
Number of subjects: 60
Study 17665078 — intervention group
Group type: COMPARATOR
Intervention: Control (1% propofol without ephedrine)
Number of subjects: 60
Study 15343012 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin supplementation (n = 20)
Number of subjects: 40
Study 15343012 — intervention group
Group type: COMPARATOR
Intervention: Conventional intensive care treatment (n = 20, controls)
Number of subjects: 40
Study 11166779 — intervention group
Group type: EXPERIMENTAL
Intervention: Etofibrate (1 g per day for 1 month)
Number of subjects: 12
Study 11166779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9699104 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral intercostal nerve block with 0.5% bupivacaine
Number of subjects: 50
Study 9699104 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 50
Study 8148216 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic rhinometry
Number of subjects: 40
Study 8148216 — intervention group
Group type: EXPERIMENTAL
Intervention: Active posterior rhinomanometry
Number of subjects: 40
Study 8148216 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine, 10 mg orally, 3 h before repeat nasal challenge with histamine
Number of subjects: 40
Study 2500006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate added to carbamazepine
Number of subjects: 7
Study 2500006 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine alone
Number of subjects: 7
Study 31126103 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen peptides (COL, 15 g/day)
Number of subjects: 57
Study 31126103 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 57
Study 31126103 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen peptides (COL) and Placebo (PLA)
Number of subjects: 57
Study 29058153 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 11
Study 29058153 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 11
Study 27394932 — intervention group
Group type: EXPERIMENTAL
Intervention: TV-1380 (150mg)
Number of subjects: 66
Study 27394932 — intervention group
Group type: EXPERIMENTAL
Intervention: TV-1380 (300mg)
Number of subjects: 66
Study 27394932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 24666826 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-molar sodium lactate infusion (3 ml/kg bolus over 15 minutes followed by 1 ml/kg/h continuous infusion for 24 hours)
Number of subjects: 40